Beijing Northland Biopharmaceutical

Beijing Northland Biopharmaceutical is a clinical-stage biotechnology company based in China, specializing in the development of gene therapies and recombinant protein drugs. The company's lead candidate, NL-003, is a non-viral plasmid gene therapy encoding human hepatocyte growth factor (HGF) currently in Phase 3 clinical trials for critical limb ischemia. Their pipeline also includes NL-002, a recombinant human thymosin beta-4 for dry eye and wound healing, and NL-005 for cardiovascular indications. Northland Biopharmaceutical operates its own R&D and manufacturing facilities, focusing on addressing unmet medical needs in vascular and ophthalmic diseases. The company is listed on the Beijing Stock Exchange and maintains a strong focus on the domestic Chinese market while exploring global opportunities.